Status:
COMPLETED
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diabetes mellitus (DM) is associated with the frequent use of polypharmacy at different times of administration and requires special attention from the patient or caregivers in order to properly treat...
Detailed Description
The first outcome of the clinical study was to measure the readmission rate through a structured pharmaceutical care model after basal hospital discharge and measure the effect of this intervention in...
Eligibility Criteria
Inclusion
- Patients with DM and other comorbidities hospitalized for any reason at HCPA
- Patients who are literate or have a literate caregiver;
- Signature in the Term of Consent.
Exclusion
- Limited ability to communicate and read in Portuguese and absence of responsible caregiver at the patient room;
- Neuropsychiatric diseases (psychosis, delirium or severe dementia);
- Terminal illness;
- Transplanted patients or users of warfarin, as these patients receive formal guidance from the HCPA pharmaceutical team;
- Auditory or visual impairment that, at the discretion of the investigator, prevents the patient from participating in the study;
- Do not have own mobile number or a close family member living in the same household.
Key Trial Info
Start Date :
September 9 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03786978
Start Date
September 9 2015
End Date
January 30 2018
Last Update
January 7 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.